Wegovy and Spain's Seguridad Social: why it isn't funded as tablets or as injections

As of November 2026, Spain's public health system (the Seguridad Social) does not fund Wegovy. That covers both the tablets that have just reached pharmacies and the weekly pen. BIFIMED, the Spanish Ministry of Health's official database of which medicines are publicly funded, lists every Wegovy presentation as ‘No financiado por resolución’ (not funded, by formal decision), so with a prescription you pay the full price. Ozempic is funded, but only for type 2 diabetes and only under certain conditions. It is not funded for weight loss.

Below we cover what each record says, why the Ministry said no, what changes between public and private prescriptions, what insurers and Spain's regional health services do, and how to check for updates yourself.

Are Wegovy tablets funded by the Seguridad Social?

No. On BIFIMED, all four presentations of Wegovy tablets (1.5, 4, 9 and 25 mg) have been listed as ‘not funded, by formal decision’ since 1 September 2026. Both of their indications are listed as ‘not included’: obesity, and overweight with a weight-related condition. According to the AEMPS (the Spanish Agency of Medicines and Medical Devices), it is a prescription-only medicine. Because it isn't funded, pharmacies dispense it on a private prescription and the buyer pays the full price.

The price is set freely by the company and no official retail price has been published. Press reports put the box of 30 × 25 mg tablets, the maintenance dose, at around €236 a month. Redacción Médica puts it at around €2,834 a year. Our guide to the price of Wegovy tablets and how they are prescribed has the details.

Novo Nordisk accepts this. Paula Barriga, its general manager in Spain, said at the launch on 3 November that ‘there is no anti-obesity drug in the pharmaceutical benefits of the National Health System’. That means patients get the drug on prescription and pay for it outside the funded market, as reported by Diariofarma.

What about the Wegovy pen? Why the Ministry said no

The injectable version isn't funded either. BIFIMED gives ‘not funded, by formal decision’ for the following pens: the 0.25, 1, 1.7 and 2.4 mg pens since 1 April 2023, the 0.5 mg in 3 ml pen since 1 November 2025, and the new 7.2 mg pen since 1 September 2026. According to Vademecum, each four-week pen costs between €179.89 and €223.64 depending on the dose. Redacción Médica attributes these prices to the price cut applied on 1 March 2026. We go through them pen by pen in our article on the monthly cost of Wegovy and why it isn't funded.

The reason is financial. According to Redacción Médica, the Interministerial Committee on Medicine Prices turned down public funding for Wegovy three times in 2025: in July, September and October. It cited ‘criteria of rationalising public spending on pharmaceutical benefits and budget impact’, one of the criteria set out in Article 92 of Spain's medicines law (Royal Legislative Decree 1/2015).

In December 2025, the Ministry of Health explained its position in three points: funding these drugs ‘requires detailed analysis’ because it involves structural changes to care, the Ministry is seeking ‘a fair and agreed price’, and ‘the companies are the only ones that can offer lower prices’.

Does the Seguridad Social cover Ozempic? Only for type 2 diabetes

Ozempic contains the same active substance as Wegovy. On BIFIMED it has been listed as ‘yes, for certain indications/conditions’ since 1 June 2019, subject to prior authorisation (visado). The conditions are strict. It is funded for adults with type 2 diabetes that isn't controlled by diet and exercise, in combination with other antidiabetic drugs (including insulin), and with a body mass index of 30 kg/m² or more. It isn't funded as monotherapy, and the 2 mg weekly dose isn't funded either.

Rybelsus, the semaglutide tablet for diabetes, works the same way. Its new presentations have been funded with prior authorisation since 1 February 2026, but only for type 2 diabetes with a BMI of 30 or more and as combination therapy. Neither drug is licensed for weight loss. The Spanish consumer organisation OCU puts it plainly: none of these analogues is funded for weight loss, and for that purpose you can only start on a private prescription. We explain how the two differ in Rybelsus or oral Wegovy for weight loss.

Does the Seguridad Social pay for Mounjaro or any weight-loss pill?

No. On BIFIMED, Mounjaro (tirzepatide, made by Lilly) has been listed as ‘not funded, by formal decision’ since 1 July 2024 at every dose, and its weight-management indication is listed as ‘not included’. Xenical (orlistat 120 mg), the other prescription obesity medicine sold in Spain, is listed as ‘not included’ for funding. In short, the public health system currently pays for no weight-loss pill or injection.

Public or private prescription: how it affects what you pay

The reduced patient contribution only applies when a funded medicine is dispensed on an official National Health System (SNS) prescription. In that case you pay only a percentage of the price, which depends on your income and personal circumstances, under Article 102 of the medicines law. Anything that isn't funded, or that is prescribed outside the funded conditions, is paid in full on a private prescription.

So in practice, as Redacción Médica pointed out on 3 November, a public-system prescription won't get you oral Wegovy at a reduced contribution. You do always need a prescription, though. It is a prescription-only medicine, and the AEMPS points out that prescription medicines cannot be sold online in Spain. For the BMI requirements and the steps involved, see how to get a prescription for oral Wegovy in Spain.

Will private health insurance cover it?

Usually not. According to the comparison site Acierto, health insurance policies generally exclude the cost of pharmacy medicines, except those given during a hospital stay. Some policies do refund part of pharmacy costs under certain conditions. We haven't found any standard policy that covers these drugs for obesity, and we haven't been able to read every insurer's terms. The sensible step is to ask your insurer in writing and check the pharmacy clause in your policy. If your insurance pays for the specialist appointment, that doesn't mean it pays for the medicine.

Does any Spanish region fund it?

None that we know of. We haven't found any region that funds these drugs for obesity. The most widely quoted regional figure comes from Osakidetza, the Basque health service: 63,778 people were treated with drugs in this class in the first half of 2026, according to a reply from the Basque Government to its Parliament. That figure doesn't separate diabetes from obesity, and the same report notes that Wegovy is not funded for weight management.

Could this change? What is being negotiated and how to stay informed

Talks are under way, but nothing has been decided. Barriga said Novo has been in talks with the Ministry of Health ‘since 2024’ and is seeking ‘to come up with an equation that is workable and sustainable for the health system’, according to El Debate. In June 2026, the company said that in Spain the tablet still needed ‘a decision on price and public funding’, and that discussions about the oral form had yet to begin. For its part, the OCU wants funding criteria set, using the United Kingdom as a reference. It suggests a BMI over 35, or over 30 in some cases, plus weight-related conditions, within structured follow-up programmes.

To check for yourself, use BIFIMED, the Ministry of Health's database of funding status for medicines. You can search by name or by national code (código nacional). On each presentation's record, look at three things:

• ‘Situación de financiación’ (funding status): this currently reads ‘No financiado por resolución’ for Wegovy and Mounjaro. If that changes, it will switch to ‘Sí’ (yes) or ‘Sí para determinadas indicaciones/condiciones’ (yes, for certain indications/conditions).
• The dates of inclusion in or exclusion from funding, which show when each status took effect.
• The authorised indications, one by one, each with its decision: included or not included, and whether prior authorisation (visado) is needed.

Key points

At present, anyone in Spain who wants medication for obesity gets it on a private prescription and pays the full price. It is worth knowing this before you start, so you can plan for the cost and not rely on funding that doesn't exist yet.

What is available in Spain today is medical weight-loss treatment that includes an initial assessment, a prescription from a registered doctor where appropriate, and ongoing follow-up. You can:

Check in a few minutes whether you're eligible